165 related articles for article (PubMed ID: 37815672)
1. The Effects of 16-HETE Enantiomers on Hypertrophic Markers in Human Fetal Ventricular Cardiomyocytes, RL-14 Cells.
Hidayat R; El-Ghiaty MA; Shoieb SM; Alqahtani MA; El-Kadi AOS
Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):709-722. PubMed ID: 37815672
[TBL] [Abstract][Full Text] [Related]
2. The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol.
Maayah ZH; Althurwi HN; El-Sherbeni AA; Abdelhamid G; Siraki AG; El-Kadi AO
Mol Cell Biochem; 2017 May; 429(1-2):151-165. PubMed ID: 28251434
[TBL] [Abstract][Full Text] [Related]
3. 16R-HETE and 16S-HETE alter human cytochrome P450 1B1 enzyme activity probably through an allosteric mechanism.
Hidayat R; Shoieb SM; Mosa FES; Barakat K; Brocks DR; Isse FA; Gerges SH; El-Kadi AOS
Mol Cell Biochem; 2023 Jul; ():. PubMed ID: 37436655
[TBL] [Abstract][Full Text] [Related]
4. 17-(R/S)-hydroxyeicosatetraenoic acid (HETE) induces cardiac hypertrophy through the CYP1B1 in enantioselective manners.
Isse FA; Alammari AH; El-Sherbeni AA; El-Kadi AOS
Prostaglandins Other Lipid Mediat; 2023 Oct; 168():106749. PubMed ID: 37244564
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol attenuates angiotensin II-induced cellular hypertrophy through the inhibition of CYP1B1 and the cardiotoxic mid-chain HETE metabolites.
Shoieb SM; El-Kadi AOS
Mol Cell Biochem; 2020 Aug; 471(1-2):165-176. PubMed ID: 32533462
[TBL] [Abstract][Full Text] [Related]
6. 5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-κB-dependent mechanism.
Maayah ZH; El-Kadi AO
Arch Toxicol; 2016 Feb; 90(2):359-73. PubMed ID: 25600587
[TBL] [Abstract][Full Text] [Related]
7.
Shoieb SM; El-Kadi AOS
Drug Metab Dispos; 2018 Aug; 46(8):1157-1168. PubMed ID: 29880629
[TBL] [Abstract][Full Text] [Related]
8. Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-κB.
Maayah ZH; Abdelhamid G; El-Kadi AO
Cell Biol Toxicol; 2015 Oct; 31(4-5):241-59. PubMed ID: 26493311
[TBL] [Abstract][Full Text] [Related]
9. Novel Synthetic Analogues of 19(S/R)-Hydroxyeicosatetraenoic Acid Exhibit Noncompetitive Inhibitory Effect on the Activity of Cytochrome P450 1A1 and 1B1.
Shoieb SM; Dakarapu R; Falck JR; El-Kadi AOS
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):613-624. PubMed ID: 34235626
[TBL] [Abstract][Full Text] [Related]
10. 19-Hydroxyeicosatetraenoic acid and isoniazid protect against angiotensin II-induced cardiac hypertrophy.
Elkhatali S; El-Sherbeni AA; Elshenawy OH; Abdelhamid G; El-Kadi AO
Toxicol Appl Pharmacol; 2015 Dec; 289(3):550-9. PubMed ID: 26454030
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole Represses Cytochrome P450 1B1 and Its Associated Arachidonic Acid Metabolites in the Heart and Protects Against Angiotensin II-Induced Cardiac Hypertrophy.
Alammari AH; Shoieb SM; Maayah ZH; El-Kadi AOS
J Pharm Sci; 2020 Jul; 109(7):2321-2335. PubMed ID: 32240690
[TBL] [Abstract][Full Text] [Related]
12. CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism.
Maayah ZH; Althurwi HN; Abdelhamid G; Lesyk G; Jurasz P; El-Kadi AO
Pharmacol Res; 2016 Mar; 105():28-43. PubMed ID: 26772815
[TBL] [Abstract][Full Text] [Related]
13. 6-Formylindolo[3,2-b]carbazole Protects Against Angiotensin II-Induced Cellular Hypertrophy through the Induction of Cytochrome P450 1A1 and Its Associated 19(S)-HETE Metabolite In Vitro.
Alammari AH; Gerges SH; Isse FA; El-Kadi AOS
Drug Metab Dispos; 2023 Jul; 51(7):833-843. PubMed ID: 37185150
[TBL] [Abstract][Full Text] [Related]
14. Identification of 19-(
Shoieb SM; El-Sherbeni AA; El-Kadi AOS
Drug Metab Dispos; 2019 Feb; 47(2):67-70. PubMed ID: 30420405
[TBL] [Abstract][Full Text] [Related]
15. Enantioselectivity in some physiological and pathophysiological roles of hydroxyeicosatetraenoic acids.
Helal SA; Gerges SH; El-Kadi AOS
Drug Metab Rev; 2024 Feb; 56(1):31-45. PubMed ID: 38358327
[TBL] [Abstract][Full Text] [Related]
16. Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy.
El-Sherbeni AA; El-Kadi AO
Biochem Pharmacol; 2014 Feb; 87(3):456-66. PubMed ID: 24300133
[TBL] [Abstract][Full Text] [Related]
17. Sex- and enantiospecific differences in the formation rate of hydroxyeicosatetraenoic acids in rat organs.
Gerges SH; Alammari AH; El-Ghiaty MA; Isse FA; El-Kadi AOS
Can J Physiol Pharmacol; 2023 Aug; 101(8):425-436. PubMed ID: 37220651
[TBL] [Abstract][Full Text] [Related]
18. Human fetal ventricular cardiomyocyte, RL-14 cell line, is a promising model to study drug metabolizing enzymes and their associated arachidonic acid metabolites.
Maayah ZH; Elshenawy OH; Althurwi HN; Abdelhamid G; El-Kadi AO
J Pharmacol Toxicol Methods; 2015; 71():33-41. PubMed ID: 25454080
[TBL] [Abstract][Full Text] [Related]
19. Subterminal hydroxyeicosatetraenoic acids: Crucial lipid mediators in normal physiology and disease states.
Shoieb SM; El-Sherbeni AA; El-Kadi AOS
Chem Biol Interact; 2019 Feb; 299():140-150. PubMed ID: 30543782
[TBL] [Abstract][Full Text] [Related]
20. The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy.
Maayah ZH; El-Kadi AO
Arch Toxicol; 2016 Jan; 90(1):119-36. PubMed ID: 26525395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
